Mundbjerg Kamilla, Chopra Sameer, Alemozaffar Mehrdad, Duymich Christopher, Lakshminarasimhan Ranjani, Nichols Peter W, Aron Manju, Siegmund Kimberly D, Ukimura Osamu, Aron Monish, Stern Mariana, Gill Parkash, Carpten John D, Ørntoft Torben F, Sørensen Karina D, Weisenberger Daniel J, Jones Peter A, Duddalwar Vinay, Gill Inderbir, Liang Gangning
USC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Genome Biol. 2017 Jan 12;18(1):3. doi: 10.1186/s13059-016-1129-3.
Slow-growing prostate cancer (PC) can be aggressive in a subset of cases. Therefore, prognostic tools to guide clinical decision-making and avoid overtreatment of indolent PC and undertreatment of aggressive disease are urgently needed. PC has a propensity to be multifocal with several different cancerous foci per gland.
Here, we have taken advantage of the multifocal propensity of PC and categorized aggressiveness of individual PC foci based on DNA methylation patterns in primary PC foci and matched lymph node metastases. In a set of 14 patients, we demonstrate that over half of the cases have multiple epigenetically distinct subclones and determine the primary subclone from which the metastatic lesion(s) originated. Furthermore, we develop an aggressiveness classifier consisting of 25 DNA methylation probes to determine aggressive and non-aggressive subclones. Upon validation of the classifier in an independent cohort, the predicted aggressive tumors are significantly associated with the presence of lymph node metastases and invasive tumor stages.
Overall, this study provides molecular-based support for determining PC aggressiveness with the potential to impact clinical decision-making, such as targeted biopsy approaches for early diagnosis and active surveillance, in addition to focal therapy.
生长缓慢的前列腺癌(PC)在一部分病例中可能具有侵袭性。因此,迫切需要用于指导临床决策、避免对惰性PC过度治疗以及对侵袭性疾病治疗不足的预后工具。PC倾向于多灶性,每个腺体有几个不同的癌灶。
在此,我们利用PC的多灶性倾向,根据原发性PC灶和匹配的淋巴结转移灶中的DNA甲基化模式对单个PC灶的侵袭性进行分类。在一组14例患者中,我们证明超过一半的病例有多个表观遗传学上不同的亚克隆,并确定了转移灶起源的主要亚克隆。此外,我们开发了一种由25个DNA甲基化探针组成的侵袭性分类器,以确定侵袭性和非侵袭性亚克隆。在一个独立队列中对该分类器进行验证后,预测的侵袭性肿瘤与淋巴结转移和侵袭性肿瘤分期的存在显著相关。
总体而言,本研究为确定PC的侵袭性提供了基于分子的支持,有可能影响临床决策,如早期诊断和主动监测的靶向活检方法,以及局部治疗。